Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$2.31
-$0.10(-4.55%)
At close: 4:00 PM EST
$2.31
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$0.51 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)1.14M
Market Cap
$24.48M
Enterprise Value$94.93M
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 13, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding51,364,520
10 Day Avg. Volume579,560
30 Day Avg. Volume1,140,316
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap3.88
Enterprise Value/Revenue1.17
Enterprise Value/Gross Profit2.03
Enterprise Value/Ebitda-15.90
Forecast
1Y Price Target
$3.38Price Target Upside46.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$116.15M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Scaling & High Gross MarginMulti-year top-line expansion and consistently healthy gross margins indicate strong unit economics and scalable demand for prostate cancer tests. This scale supports fixed-cost absorption and creates a realistic path to operating leverage and eventual profitability if SG&A growth is managed.
Commercial Integration & Sales EfficiencySuccessful integration of acquired sales teams and customer migration materially increases sales productivity and enables cross-selling of a broader prostate cancer menu. Durable commercial efficiencies can raise lifetime customer value and lower incremental customer acquisition costs over time.
AI & Clinical Differentiation InitiativesBuilding an AI data platform and embedding AI endpoints into a major clinical trial strengthens clinical differentiation and long-term defensibility. AI-driven prognostic improvements can increase guideline adoption, payer acceptance, and price/margin resilience over multiple years.
Bears Say
Balance-Sheet StrainSharp debt increases and negative equity undermine financial flexibility and raise refinancing and covenant risk. Structural leverage reduces ability to invest in commercial expansion or R&D without external funding and increases dilution or financing costs over the medium term.
Negative Cash GenerationPersistent negative operating and free cash flow means the business remains reliant on external capital to fund operations and integration. Continued cash burn elevates dilution risk and can constrain strategic investments until consistent positive FCF is achieved.
Resolve Exit & Recoupment Liquidity RiskExiting Resolve reduces revenue diversification and triggers restructuring costs, while a contested Medicare recoupment and a $15M earn‑out materially cut the cash buffer. This combination heightens execution and liquidity risk during integration and commercialization of core products.
MDxHealth News
MDXH FAQ
What was Mdxhealth S.A.’s price range in the past 12 months?
Mdxhealth S.A. lowest stock price was $0.51 and its highest was $5.33 in the past 12 months.
What is Mdxhealth S.A.’s market cap?
Mdxhealth S.A.’s market cap is $24.48M.
When is Mdxhealth S.A.’s upcoming earnings report date?
Mdxhealth S.A.’s upcoming earnings report date is Aug 13, 2026 which is in 41 days.
How were Mdxhealth S.A.’s earnings last quarter?
Mdxhealth S.A. released its earnings results on May 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.045.
Is Mdxhealth S.A. overvalued?
According to Wall Street analysts Mdxhealth S.A.’s price is currently Undervalued.
Does Mdxhealth S.A. pay dividends?
Mdxhealth S.A. does not currently pay dividends.
What is Mdxhealth S.A.’s EPS estimate?
Mdxhealth S.A.’s EPS estimate is -0.19.
How many shares outstanding does Mdxhealth S.A. have?
Mdxhealth S.A. has 51,364,520 shares outstanding.
What happened to Mdxhealth S.A.’s price movement after its last earnings report?
Mdxhealth S.A. reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went down -49.538%.
Which hedge fund is a major shareholder of Mdxhealth S.A.?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mdxhealth S.A.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDXH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously positive outlook: operationally the company is refocusing on its high-growth prostate cancer franchise with clear commercial integration wins (ExoDx transition, sales cross-training), AI initiatives, and a raised 2026 revenue target implying 20–26% growth. However, material near-term headwinds exist — most notably the strategic exit of the Resolve UTI business, a Novitas recoupment notice up to $10.4M, pro forma margin compression, and a wider operating loss driven by the ExoDx acquisition and integration — all of which create execution and liquidity considerations in the short term. Overall, management frames the Resolve exit as a proactive, value-accretive repositioning to prioritize scalable core growth while defending against payer recoupment risk.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$3.38
▲(46.10% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.45% Mutual Funds
20.13% Other Institutional Investors
78.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---